Mr. Speaker, part (a) of this question cannot be answered definitively. There are currently 8121 marketed human prescription drugs by drug identification number, DIN, as of April 30, 2015. This number includes both innovative and generic drugs. Many of these various drugs, vaccines and prescription medications were authorized decades ago using a paper-based system. As such, Health Canada databases do not capture detailed information on the evidence used to approve the drugs. A fact sheet on how drugs are reviewed is available at: www.hc-sc.gc.ca/dhp-mps/prodpharma/activit/fs-fi/reviewfs_examenfd-eng.php.
With regard to (b), the defined scope for this response was all submissions that received a notice of compliance, NOC, in calendar year 2014 that met the criteria for the summary basis of decision, SBD. Please see: www.hc-sc.gc.ca/dhp-mps/prodpharma/sbd-smd/index-eng.php. This includes all new active substances, all priority-new active substances and all subsequent entry biologics that received an NOC in 2014. A total of 27 submissions were within the scope for calendar year 2014. Of these 27 submissions, 63% contained double-blind clinical studies to support efficacy. Submissions that fall outside the scope of the summary basis of decision project are difficult to search by clinical study due to database and IT limitations.